What is the role of lapatinib in the treatment of HER2-positive breast cancer?

Updated: Jul 16, 2020
  • Author: Maurie Markman, MD, MS; Chief Editor: Karl S Roth, MD  more...
  • Print


A study that evaluated the efficacy of lapatinib in HER2-negative and HER2-uncharacterized metastatic breast cancer concluded that although patients with HER2-negative or HER2-untested metastatic breast cancer did not experience benefit from the addition of lapatinib to paclitaxel, first-line therapy with paclitaxel-lapatinib significantly improved clinical outcomes in patients who were HER2-positive. [13]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!